Four-Year Follow-Up of Polyalkylimide Gel Use for the Treatment of HIV-Associated Lipoatrophy

REFERENCES

• Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Read. 2000;10(9):546–550.
   PubMedGoogle Scholar
• Oette M, Juretzko P, Kroidl A, et al. Lipodystrophy syn-drome and self-assessment of well-being and physical appearance in HIV-positive patients. AIDS Patient Care STDS. 2002;16(9):413–417.
   PubMed Web of Science ®Google Scholar
• Santos CP, Felipe YX, Braga PE, Ramos D, Lima RO, Segurado AC. Self-perception of body changes in persons living with HIV/AIDS: prevalence and associated factors. AIDS. 2005;19(Suppl 4):14–21.
   PubMed Web of Science ®Google Scholar
• Duran S, Saves M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001;15(18):2441–2444.
   PubMed Web of Science ®Google Scholar
• Martin A, Smith DE, Carr A, et al. Reversibility of lipoatro-phy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS. 2004;18(7):1029–1036.
   PubMed Web of Science ®Google Scholar
• Sutinen J. Interventions for managing antiretroviral therapy-associated lipoatrophy. Curr Opin Infect Dis. 2005;18(1):25–33.
   PubMed Web of Science ®Google Scholar
• Martin A, Mallon PW. Therapeutic approaches to combat-ing lipoatrophy: do they work ? J Antimicrob Chemother 2005;55(5):612–615.
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Brown S, Lysakova L, Barton SE. Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy. HIV Med. 2006;7(3): 181–185.
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Lysakova L, Brown S, et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoat-rophy in persons with HIV infection. HIV Med. 2004;5(2): 82–87.
   PubMed Web of Science ®Google Scholar
• Pacini S, Ruggiero M, Morucci G, Cammarota N, Proto-papa C, Gulisano M. Bio-Alcamid: a novelty for recon-structive and cosmetic surgery. It J Anat Embryol. 2002;107:209–214.
   PubMedGoogle Scholar
• Protopapa C, Sito G, Caporale D, Cammarota N. Bio-Alcamid in drug-induced lipodystrophy. J Cosmet Laser Ther 2003;5(3-4):226–230.
   PubMedGoogle Scholar
• Treacy PJ, Goldberg DJ. Use of a biopolymer polyalkyl-imide filler for facial lipodystrophy in HIV-positive patients undergoing treatment with antiretroviral drugs. Dermatol Surg. 2006;32(6):804–808.
   PubMed Web of Science ®Google Scholar
• Luis C, Casavantes, Martin I. Stability, tolerance and safety of Bio-Alcamid (polyalkylimide) gel, the injectable endo-prosthesis for correction of HIV related facial lipoatrophy (2nd part). JSurginews. 2004;4:3.
   Google Scholar
• Loutfy MR, Raboud JM, Antoniou T, et al. Immediate versus delayed polyalkylimide gel injections to cor-rect facial lipoatrophy in HIV-positive patients. AIDS. 2007;21(9)1 147–1155.
   Web of Science ®Google Scholar
• Antoniou T, Raboud JM, Kovacs C, Diong C, Brunetta J, Smith G, et al. Long-term efficacy and safety of polyalkyl-imide gel for the treatment of HIV-associated lipoatrophy. AIDS Care. 2009;21(10):1247–1252.
   PubMed Web of Science ®Google Scholar
• Fontdevila J, Martinez E, Guisantes E, Serra-Renom JM, Gatell J. Complications with Bioalcamid in the aes-thetic treatment of lipoatrophy [abstract]. Antiviral Ther. 2006;11:L60 ( abstract 100).
   Google Scholar
• Karim RB, Hage JJ, van Rozelaar L, Lange CA, Raaijmakers J. Complications of polyalkylimide 4% injections (Bio-Alcamid): a report of 18 cases. J Plast Reconstr Aesthet Surg. 2006;59(12):1409–1414.
   PubMed Web of Science ®Google Scholar
• Goldan O, Georgiou I, Grabov-Nardini G, et al. Early and late complications after a nonabsorbable hydro-gel polymer injection: a series of 14 patients and novel management. Dermatol Surg. 2007;33\(Suppl 2):199–206; discussion S206.
   PubMed Web of Science ®Google Scholar
• Goldan O, Georgiou I, Farber N, Winkler E, Haik J, Orenstein A. Late-onset facial abscess formation after cosmetic soft tissue augmentation with Bio-Alcamid. Aes-thet Surg. 2007;27(4):416–418.
   PubMedGoogle Scholar
• Jones DH, Carruthers A, Fitzgerald R, Sarantopoulos GP, Binder S. Late-appearing abscesses after injections of nonabsorbable hydrogel polymer for HIV-associated lipoatrophy. Dermatol Surg. 2007;33(Suppl 2):193–198.
   Web of Science ®Google Scholar
• Alijotas-Reig J, Garcia-Gimenez V, Mir6-Mur F, Vilardell-Tarres M. Delayed immune-mediated adverse effects of polyalkylimide dermal fillers: clinical findings and long-term follow-up. Arch Dermatol. 2008;144(5):637–642.
   PubMed Web of Science ®Google Scholar
• Ocampo-Candiani J, Sobrevilla-Ondarza S, Velazquez-Arenas L, Vazquez-Martinez OT. Complications of a poly-alkylimide implant in a patient with facial trauma. Dermatol Surg. 2008;34(9)1 280–1282.
   PubMed Web of Science ®Google Scholar
• Chrastil-LaTowsky B, Wesley NO, MacGregor JL, Kaminer MS, Arndt KA. Delayed inflammatory reaction to bio-alcamid polyacrylamide gel used for soft-tissue augmenta-tion. Arch Dermatol. 2009;145(11):1309–1312.
   PubMed Web of Science ®Google Scholar
• Haneke E. Risks of permanent fillers. Expert Review Dermatol. 2009;4(3):271–283.
   Google Scholar
• Ross AH, Malhotra R. Long-term orbitofacial complica-tions of polyalkylimide 4% (bio-alcamid). Ophthal Plast Reconstr Surg. 2009;25(5):394–397.
   PubMed Web of Science ®Google Scholar
• Monheit GD, Rohrich RJ. The nature of long-term fillers and the risk of complications. Dermatol Surg. 2009;35 (Supp12)1598–1608.
   PubMed Web of Science ®Google Scholar
• Campana M, Lazzeri D, Rosato L, et al. Late-onset gluteal Escherichia coli abscess formation 7 years after soft tissue augmentation with Bio-Alcamid in a HIV-positive patient. J Plast Reconstr Aesthet Surg. 2010;63(9):709–710.
   PubMed Web of Science ®Google Scholar
• Nadarajah J, Collins M, Loutfy MR, Walmsley S. Infectious complications of Bio-Alcamid soft tissue endoprosthesis treatment of HIV-associated facial lipoatrophy. Antiviral Ther. 2010;15(Suppl 4):A22.
   Google Scholar
• Schelke L. Complications after treatment with polyalkyl-imide. Dermatol Surg. 2011;37(1)1 25.
   Web of Science ®Google Scholar
• Loutfy MR, Kovacs CM, Raboud J, Halpenny R, Beninger F. Pilot study of the safety, clinical efficacy and impact on quality of life using Bio-Alcamid for the reconstructive treatment of antiretroviral-induced facial lipoatrophy in HIV-positive individuals [oral abstract 147]. In: Program and abstracts of the 14th Annual Canadian Conference on HIV/AIDS Research; May 2005.
   Google Scholar
• James J, Carruthers A, Carruthers J. HIV-associated facial lipoatrophy. Dermatol Surg. 2002; 28(11):979–986.
   PubMed Web of Science ®Google Scholar
• Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res. 1997; 6(6):481–493.
   PubMed Web of Science ®Google Scholar
• Savard J, Laberge B, Gauthier JG, Ivers H, Bergeron MG. Evaluating anxiety and depression in HIV-infected patients. J Pers Assess. 1998;71(3):349–367.
   PubMed Web of Science ®Google Scholar
• Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLOL). J Investig Dermatol Symp Proc. 2004;9(2):169–180.
   PubMed Web of Science ®Google Scholar
• Little JW, Jacobson JJ, Lockhart PB. The dental treat-ment of patients with joint replacements: a position paper from the American Academy of Oral Medicine. J Am Dent Assoc. 2010;141;667–671
   PubMed Web of Science ®Google Scholar
• American Academy of Orthopaedic Surgeons. Information statement: antibiotic prophylaxis for bacteremia in patients with joint replacements. www.aaos.org/about/papers/advistmt/1033.asp. Accessed September 23, 2011.
   Google Scholar